Appl. No.

10/688,198

Filed

October 17, 2003

REMARKS

In the Office Action dated April 24, 2006, the Examiner has required the election of one of two groups of claims. In response, the Applicants hereby elect Group I (consisting of Claims 1-25, drawn to methods of producing antibody fragments) without traverse.

The Examiner has further required a species election of an endogenous antibody cleaving enzyme. The Applicants hereby elect Species C, aspartyl protease. The Applicant respectfully submits that Claims 10 and 18-25 are specifically directed to methods in which an aspartyl protease is used as an endogenous antibody cleaving enzyme.

The Examiner has further required a species election of an antibody producing cell line. The Applicants hereby elect Species AA, Chinese hamster ovary cells. The Applicant respectfully submits that Claim 12 is specifically directed to methods in which Chinese hamster ovary cells (CHO-DG44 cells) are used as an antibody producing cell line.

The undersigned has made a good faith effort to respond to all the issues raised in the outstanding Office Action, and respectfully submits that the case is now in condition for examination on the merits. Nevertheless, if any undeveloped issues remain, or if any issues require clarification, the Examiner is respectfully requested to call the undersigned to discuss such issues.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 5/23/06

By:

Erik T. Anderson Registration No. 52,559

Attorney of Record

Customer No. 20,995

(619) 235-8550

2597082\051206\lvo